FDA gets early warning system for drug shortages—before patients run out
S. 2665 — Drug Shortage Prevention Act of 2025 · Filed by Amy Klobuchar (D-MN) · 5 cosponsors · Introduced Aug 1, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires manufacturers of critical drugs (those that are life-supporting, life-sustaining, or used to treat serious diseases) to notify the FDA before discontinuing or interrupting production, or when they cannot meet demand due to supply chain issues. Manufacturers must provide at least 6 months' notice for planned discontinuances, notify within 10 business days for unexpected supply disruptions, and disclose their suppliers of active ingredients and materials. The FDA must then share this information with doctors, hospitals, and patient groups to help prevent shortages.
Why we flagged it
The bill's core mechanism is a mandatory notification and reporting regime for pharmaceutical manufacturers, designed to improve FDA and healthcare-provider visibility into drug supply chains and prevent shortages through early warning.
What the text implies
- Manufacturers may face competitive pressure to disclose proprietary supplier relationships and sourcing strategies, potentially benefiting competitors or foreign actors with access to FDA filings.
- The 6-month advance-notice requirement may incentivize manufacturers to discontinue marginal or low-profit drugs earlier rather than risk regulatory scrutiny, potentially reducing availability of niche treatments.
The full analysis lists 4 implications of this text.
Who it affects
Ordinary citizens gain earlier warning of potential drug shortages and better supply-chain visibility, enabling healthcare providers and patients to plan ahead and reducing the risk of critical medications becoming unavailable. The bill imposes transparency and planning obligations on manufacturers but does not restrict patient access or increase out-of-pocket costs.